Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)AAP Issues Updated Guidance on Palivizumab Use for the 2022-2023 RSV Season

The updated AAP guidance “recommends programmatic consideration of providing more than 5 consecutive doses of palivizumab depending on the duration of the current RSV surge in a given region of the country.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form